ClinicalTrials.gov
public full text
Public Domain
Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis
Ulcerative colitis patients treated with Infliximab (IFX) in deep remission after at least 12 months of treatment will be randomized to continue IFX or to stop IFX and start Azathioprine (AZA). Each patient will be followed for 12 months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis#1058577
- A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission#1095973
- Efficacy of Infliximab as a Rescue Therapy in Pediatric Acute Severe Colitis#901279
- Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI®)#804066
- Upadacitinib therapy during hospitalisation for moderate to severe ulcerative colitis in patients previously treated with infliximab: a UK tertiary care centre experience and literature review#295977
Record · ID 802591
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive